RxDoctor Payments Data

Jennifer Sterner, APRN

Adult Health · North Platte, NENPI 1184974792

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 59 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Novartis at 40.9% of the total.

$1,101in general payments, 2019–2025

Across 59 payments — averaging $18.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$450
  • E.r. Squibb & Sons, L.L.C.$232
  • Amgen$88
  • Boehringer Ingelheim$73
  • Itamar Medical Inc$56
  • Lexicon Pharmaceuticals, Inc.$35
  • plus $166 from 7 others

What the payments were for

  • Food & beverage$1,101100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,101 in reported general payments places this provider in the 70th percentile of 58 adult health providers in Nebraska.

See all adult health providers in Nebraska

Medicare billing

Part B allowed, 2024
$113,925
Medicare patients
589
Services billed
2,062

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban176$127,590
XareltoRivaroxaban89$53,132
Repatha SureclickEvolocumab85$49,354
EntrestoSacubitril/Valsartan41$40,912
BrilintaTicagrelor37$18,580
Potassium Chloride177$14,740
JardianceEmpagliflozin19$13,858
Praluent PenAlirocumab18$8,524
Atorvastatin Calcium500$5,492
Metoprolol Succinate293$4,798
Ranolazine ErRanolazine85$4,695
Ezetimibe210$4,206
Flecainide Acetate44$3,612
Prasugrel Hcl17$3,599
Rosuvastatin Calcium199$3,175

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$127,590176 claims
Johnson & JohnsonXarelto$26$53,13289 claims
NovartisEntresto$450$40,91241 claims
Boehringer IngelheimJardiance$73$13,85819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 58 adult health providers in Nebraska.

Other adult health in North Platte

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →